FAP and Miyoshi myopathy: MP0250 targeting VEGF/HGF is in phase 2 testing for r/r MM (NCT03136653), MP0310 (aka AMG 506) directed against the fibroblast activation protein [182] (FAP)/4-1BB, and MP0274 targeting two different HER2 epitopes are in phase 1 testing (NCT04049903, NCT03084926), while MP0317 targeting FAP/CD40, and various T-cell redirecting DARPins (CD3-engaging) are expected to follow soon.